NAPLEX Quiz: Patient Parameters And Laboratory Measures

What this quiz covers

This quiz focuses on Patient Parameters And Laboratory Measures, giving you a quick way to practice the rules, question types, and explanations that matter most for NAPLEX.

How to use this quiz

Try each quiz question before looking at the correct answer. Use the explanations to review missed ideas, then come back to similar questions until the pattern feels familiar.

Question 1

1. Continue warfarin 6 mg daily because the INR elevation is expected with mechanical valves
2. Hold warfarin and administer oral vitamin K (low dose) due to supratherapeutic INR without bleeding; reassess interacting antibiotic (correct answer)
3. Increase warfarin to 8 mg daily because TMP-SMX decreases INR through enzyme induction
4. Stop warfarin permanently and switch to apixaban because it is preferred for mechanical valves

Explanation: This question evaluates management of warfarin-antibiotic interactions in high-risk anticoagulation scenarios, specifically with mechanical heart valves. The critical finding is an INR of 6.2 (goal 2.5-3.5) after 5 days of TMP-SMX, a known warfarin potentiator, without signs of bleeding. Option B is correct because it appropriately manages the significantly elevated INR with low-dose oral vitamin K (1-2.5 mg) to partially reverse anticoagulation without causing subtherapeutic levels, while addressing the causative drug interaction. Option A is incorrect as an INR of 6.2 is dangerously high even for mechanical valves and requires intervention. Option C is incorrect because TMP-SMX inhibits (not induces) CYP2C9, increasing warfarin effect and INR. Option D is dangerously incorrect as DOACs like apixaban are contraindicated in mechanical valves due to increased thrombotic risk. TMP-SMX can increase INR by 2-3 fold through CYP inhibition and displacement from protein binding; consider empiric warfarin dose reduction of 25-50% when starting this antibiotic in stable patients.

Question 2

1. Continue warfarin 5 mg PO daily and recheck INR in 4 weeks
2. Hold warfarin for 1–2 doses and recheck INR within 24–72 hours; assess need to change interacting antibiotic (correct answer)
3. Administer vitamin K 10 mg IV now and discontinue warfarin permanently
4. Increase warfarin to 7.5 mg PO daily because INR is above goal due to lab variability

Explanation: This question tests the management of warfarin drug interactions and supratherapeutic INR without bleeding. The key patient-specific factor is the 70-year-old female's recent initiation of TMP-SMX, a known warfarin potentiator, leading to an INR of 5.6. Holding warfarin for 1–2 doses and rechecking INR within 24–72 hours while assessing the need to change the antibiotic is the best step to safely manage the interaction and restore therapeutic INR. Continuing without adjustment risks bleeding, administering high-dose vitamin K and discontinuing warfarin permanently is excessive without bleeding, and increasing warfarin is incorrect as the INR is already elevated. No distractor considers the interaction mechanism. A clinical pearl is to anticipate INR elevations with antibiotics like TMP-SMX that inhibit warfarin metabolism and monitor closely. This framework emphasizes proactive interaction management to prevent complications in anticoagulation therapy.

Question 3

1. A1c 7.4%
2. eGFR 28 mL/min/1.73 m$^2$ (correct answer)
3. K 5.0 mEq/L
4. AST/ALT within normal limits

Explanation: This question tests the recognition of contraindications for SGLT2 inhibitors in type 2 diabetes management. The key patient-specific factor is the 59-year-old male's eGFR of 28 mL/min, which is below the threshold for dapagliflozin continuation. The eGFR 28 mL/min indicates a need for therapy modification as SGLT2 inhibitors are contraindicated or require discontinuation when eGFR <30-45 mL/min depending on the agent. A1c 7.4% is at goal, K 5.0 is normal, and normal AST/ALT do not warrant change. Distractors are benign labs. A clinical pearl is to reassess eGFR periodically in T2DM patients on SGLT2 inhibitors for timely adjustments. This approach prevents renal complications in CKD progression.

Question 4

1. Initiate high-intensity statin therapy (e.g., atorvastatin 40–80 mg PO daily) (correct answer)
2. Initiate low-intensity statin therapy (e.g., simvastatin 10 mg PO nightly) because LDL is <190 mg/dL
3. Start fenofibrate monotherapy because triglycerides are >200 mg/dL
4. No lipid-lowering therapy is indicated because A1c is normal

Explanation: This question tests application of ASCVD risk assessment and statin intensity selection for primary prevention based on multiple risk factors. The key parameters are LDL 176 mg/dL, HDL 38 mg/dL, current smoking, and untreated hypertension in a 52-year-old male. Option A is correct because this patient has multiple major ASCVD risk factors (smoking, hypertension, low HDL) with an LDL 70-189 mg/dL, indicating need for high-intensity statin therapy to achieve ≥50% LDL reduction. Option B is incorrect as low-intensity statins are inadequate given his high ASCVD risk and would achieve only 20-30% LDL reduction. Option C is incorrect because statins are first-line for LDL reduction and ASCVD prevention; fibrates are not appropriate monotherapy despite elevated triglycerides. Option D is incorrect - normal A1c doesn't negate the need for lipid therapy given his other significant risk factors. For primary prevention, calculate 10-year ASCVD risk and consider risk enhancers like smoking; this patient likely has >20% 10-year risk warranting high-intensity statin therapy.

Question 5

1. Stop St. John's wort and recheck INR soon; adjust warfarin only if needed based on follow-up INR (correct answer)
2. Hold warfarin for 2 doses and recheck INR in 1 week
3. Administer vitamin K 5 mg PO now because INR is low
4. Switch to rivaroxaban 20 mg PO daily because INR is subtherapeutic

Explanation: This question tests the management of warfarin interactions with herbal supplements like St. John's wort. The key patient-specific factor is the 63-year-old female's recent St. John's wort use, an inducer causing subtherapeutic INR of 1.4. Stopping St. John's wort and rechecking INR soon with warfarin adjustment if needed is the best step to restore anticoagulation efficacy. Holding warfarin or switching to apixaban is premature, and vitamin K would lower INR further. Distractors miss induction effect. A clinical pearl is to counsel on herbal interactions with warfarin and monitor INR after changes. This framework prevents thrombotic risks from subtherapeutic levels.

Question 6

1. Continue levofloxacin 750 mg PO daily without adjustment
2. Change to levofloxacin 750 mg PO once, then 750 mg PO every 48 hours (correct answer)
3. Change to levofloxacin 250 mg PO daily
4. Discontinue levofloxacin and start azithromycin 500 mg PO daily due to renal impairment

Explanation: This question tests the concept of antimicrobial dosing adjustments in patients with chronic kidney disease to prevent toxicity. The key patient-specific factor is the 78-year-old female's CKD stage 3b with an estimated CrCl of approximately 21 mL/min based on her age, weight, and SCr of 1.8 mg/dL. Changing to levofloxacin 750 mg PO once, then 750 mg PO every 48 hours is the best choice as it aligns with renal dosing guidelines for levofloxacin in pneumonia for CrCl 20-49 mL/min, ensuring therapeutic levels without accumulation. Continuing the daily dose without adjustment is incorrect as it risks toxicity due to reduced clearance, while reducing to 250 mg daily is suboptimal for pneumonia treatment efficacy, and switching to azithromycin is unnecessary since levofloxacin remains appropriate with adjustment. Adding ibuprofen is not indicated and could worsen renal function. A practical clinical pearl is to always calculate CrCl using the Cockcroft-Gault equation for renally cleared drugs and consult dosing guidelines for adjustments in CKD. This framework helps prevent adverse effects while maintaining efficacy in renally impaired patients.

Question 7

1. WBC 3.0 x10$^3$/mm$^3$ suggesting bone marrow suppression; avoid TMP-SMX with methotrexate (correct answer)
2. AST 52 U/L indicating no concern because it is within normal range
3. SCr 1.4 mg/dL indicating improved renal function; increase TMP-SMX to 2 tablets BID
4. ALT 60 U/L indicating the need to start high-dose acetaminophen for hepatoprotection

Explanation: This question tests recognition of drug-drug interactions causing hematologic toxicity, specifically the methotrexate-trimethoprim interaction. The critical lab value is the WBC of 3.0 x10³/mm³ (normal 4.0-11.0), indicating leukopenia in a patient on concurrent methotrexate and TMP-SMX. Option A is correct because both methotrexate and trimethoprim are antifolate drugs that can cause additive bone marrow suppression, and this combination should generally be avoided or used with extreme caution. Option B is incorrect because AST 52 U/L is actually elevated (normal 10-40) and may indicate methotrexate hepatotoxicity. Option C is incorrect as the elevated SCr indicates worsening (not improved) renal function, and increasing the dose would be dangerous. Option D is incorrect because elevated transaminases contraindicate high-dose acetaminophen, which would worsen hepatotoxicity. When patients on methotrexate require antibiotics, avoid trimethoprim-containing products and monitor CBC closely, as this interaction can cause severe pancytopenia even with low-dose methotrexate.

Question 8

1. Continue zolpidem 10 mg nightly because hepatic dysfunction does not affect zolpidem
2. Recommend lowering zolpidem dose (e.g., 5 mg nightly) due to hepatic impairment and CNS risk (correct answer)
3. Start disulfiram 500 mg PO daily immediately because LFTs are elevated
4. Increase acetaminophen to 4,000 mg/day maximum because INR is elevated

Explanation: This question tests medication adjustments in hepatic impairment to reduce adverse effects. The key patient-specific factor is the 50-year-old male's alcoholic hepatitis with elevated LFTs and INR, increasing zolpidem's half-life. Recommending zolpidem 5 mg nightly is best to minimize CNS depression in liver disease. Continuing 10 mg ignores impairment, starting disulfiram is premature, and increasing acetaminophen risks hepatotoxicity. Distractors overlook hepatic metabolism. A clinical pearl is to halve doses of sedatives like zolpidem in cirrhosis. This framework promotes safe insomnia management in liver disease.

Question 9

1. Start levofloxacin 750 mg PO every 24 hours with no renal adjustment
2. Start levofloxacin 750 mg PO once, then 750 mg PO every 48 hours due to reduced CrCl (correct answer)
3. Start levofloxacin 250 mg PO every 8 hours due to reduced CrCl
4. Avoid levofloxacin because penicillin allergy contraindicates fluoroquinolones

Explanation: This question tests the ability to calculate creatinine clearance and apply appropriate renal dosing adjustments for antibiotics in elderly patients. The key patient-specific factor is the severely reduced CrCl of approximately 20 mL/min in this 72-year-old female with pyelonephritis. Option B is correct because levofloxacin requires significant dose adjustment when CrCl is 20-49 mL/min - specifically, the standard 750 mg dose is given initially, followed by 750 mg every 48 hours instead of daily. Option A is incorrect as it fails to account for the renal impairment, risking drug accumulation and toxicity. Option C incorrectly suggests more frequent dosing with a lower dose, which is not the standard renal adjustment for levofloxacin. Option D is incorrect because penicillin allergy does not contraindicate fluoroquinolones - these are structurally unrelated drug classes. When adjusting fluoroquinolone doses for renal impairment, maintain the same individual dose but extend the dosing interval to prevent accumulation while ensuring adequate peak concentrations for bacterial killing.

Question 10

1. Hold warfarin for 1–2 doses and reduce the maintenance dose; recheck INR within 1 week (correct answer)
2. Administer vitamin K 10 mg IV now and continue warfarin at the same dose
3. Continue warfarin 5 mg daily because the INR is within goal for atrial fibrillation
4. Increase warfarin to 7.5 mg daily because amiodarone lowers INR over time

Explanation: This question evaluates the management of drug-drug interactions affecting warfarin anticoagulation, specifically the amiodarone-warfarin interaction. The critical patient parameter is the elevated INR of 4.6 (goal 2.0-3.0) occurring 10 days after starting amiodarone, a potent CYP2C9 inhibitor. Option A is correct because it appropriately manages the supratherapeutic INR without bleeding by holding warfarin temporarily and reducing the maintenance dose, with appropriate follow-up monitoring. Option B is incorrect as IV vitamin K 10 mg is excessive for an asymptomatic patient and would likely cause subtherapeutic anticoagulation. Option C is wrong because an INR of 4.6 exceeds the therapeutic range for atrial fibrillation and increases bleeding risk. Option D is incorrect because amiodarone increases (not decreases) INR by inhibiting warfarin metabolism. The amiodarone-warfarin interaction typically requires a 30-50% warfarin dose reduction, and the effect can persist for weeks after amiodarone discontinuation due to its long half-life.

Question 11

1. Add empagliflozin 10 mg PO daily (correct answer)
2. Increase metformin to 1500 mg PO BID
3. Stop metformin due to A1c > 9% and start insulin glargine 10 units nightly as monotherapy
4. Add sitagliptin 25 mg PO daily due to elevated A1c

Explanation: This question tests the management of type 2 diabetes in patients with atherosclerotic cardiovascular disease and suboptimal glycemic control. The key patient-specific factor is the 64-year-old male's history of ASCVD (prior MI) and elevated A1c of 9.2% despite current therapy. Adding empagliflozin 10 mg PO daily is the best choice as SGLT2 inhibitors are recommended for T2DM patients with ASCVD to reduce cardiovascular risk and improve glycemic control. Increasing metformin to 1500 mg BID is suboptimal without addressing CV risk, stopping metformin for insulin monotherapy overlooks combination therapy benefits, and adding sitagliptin 25 mg is incorrect as the dose is renally adjusted unnecessarily given normal eGFR. No distractor addresses the CV benefit priority. A clinical pearl is to prioritize agents like SGLT2 inhibitors or GLP-1 agonists in T2DM with ASCVD per ADA guidelines. This approach integrates patient comorbidities into therapy selection for better outcomes.

Question 12

1. Increase semaglutide to 2 mg SC weekly because A1c is above 6.5%
2. Continue current diabetes regimen; no adjustment is needed based on A1c (correct answer)
3. Stop metformin because A1c is at goal
4. Add glyburide 5 mg PO daily to further lower A1c

Explanation: This question tests glycemic goal assessment in type 2 diabetes with comorbidities. The key patient-specific factor is the 69-year-old female's A1c of 6.7% with ASCVD and CKD, which is at or below individualized goals. Continuing the current regimen without adjustment is best as A1c is controlled without hypoglycemia risk. Increasing semaglutide or adding glyburide is unnecessary, and stopping metformin overlooks its benefits. Distractors assume stricter goals. A clinical pearl is to individualize A1c targets to <7-8% in elderly with comorbidities per ADA. This approach balances control and safety.

Question 13

1. Continue hydrochlorothiazide and add sodium chloride tablets because thiazides do not cause hyponatremia
2. Hold hydrochlorothiazide and contact the prescriber due to symptomatic hyponatremia (correct answer)
3. Increase hydrochlorothiazide to 50 mg daily to correct sodium by increasing diuresis
4. Add spironolactone 25 mg daily to rapidly increase serum sodium

Explanation: This question evaluates recognition and management of thiazide-induced hyponatremia, a potentially serious adverse effect requiring prompt intervention. The critical lab value is the sodium of 124 mEq/L (normal 135-145) with low serum osmolality, presenting with neurologic symptoms (confusion, nausea) after 3 weeks of hydrochlorothiazide therapy. Option B is correct because symptomatic hyponatremia requires immediate discontinuation of the causative agent and medical evaluation for appropriate sodium correction. Option A is dangerously incorrect - thiazides are a common cause of hyponatremia, and adding sodium tablets without addressing the underlying cause could worsen the situation. Option C is incorrect as increasing the thiazide dose would worsen hyponatremia. Option D is incorrect because spironolactone can also cause hyponatremia and would not rapidly correct sodium levels. Thiazide-induced hyponatremia typically occurs within 2-4 weeks of initiation, and risk factors include older age, female sex, and concurrent SSRIs (which this patient is taking).

Question 14

1. Cefepime 2 g IV every 8 hours with no renal adjustment
2. Cefepime 2 g IV every 24 hours with renal dose adjustment for CrCl ~18 mL/min (correct answer)
3. Cefepime 2 g IV every 12 hours because reduced CrCl requires more frequent dosing
4. Avoid cefepime because macrolide allergy contraindicates cephalosporins

Explanation: This question evaluates appropriate antibiotic dosing in severe chronic kidney disease, requiring creatinine clearance calculation and application of renal dosing guidelines. The key parameter is the severely reduced CrCl of approximately 18 mL/min in this CKD stage 4 patient with pneumonia. Option B is correct because cefepime requires significant dose adjustment when CrCl <30 mL/min - specifically, the dose remains 2 g but the interval extends to every 24 hours to prevent accumulation while maintaining adequate peak concentrations. Option A is incorrect as it ignores the severe renal impairment, risking cefepime neurotoxicity. Option C incorrectly suggests more frequent dosing with renal impairment, which would increase toxicity risk. Option D is incorrect because macrolide allergy (azithromycin) does not contraindicate cephalosporins - these are unrelated drug classes. For renally eliminated antibiotics in CKD, maintain the loading dose but extend dosing intervals based on CrCl to achieve therapeutic peaks while preventing accumulation and toxicity.

Question 15

1. Continue lithium and hydrochlorothiazide; recheck lithium level in 6 months
2. Hold lithium and notify prescriber; evaluate stopping hydrochlorothiazide due to increased lithium levels (correct answer)
3. Increase lithium to 600 mg PO TID because the level is within range for acute mania
4. Add NSAID therapy for tremor because it lowers lithium concentrations

Explanation: This question tests lithium toxicity recognition and management in the context of drug interactions. The key patient-specific factor is the 56-year-old female's elevated lithium level of 1.8 mEq/L with symptoms, following hydrochlorothiazide initiation which reduces lithium clearance. Holding lithium and evaluating stopping hydrochlorothiazide is the best adjustment to resolve toxicity. Continuing or increasing lithium ignores toxicity, and adding NSAIDs would worsen levels. Distractors miss interaction. A clinical pearl is to monitor lithium levels closely with diuretics or NSAIDs. This approach prevents severe neurotoxicity in bipolar management.

Question 16

1. Continue oseltamivir 75 mg PO BID because short courses do not require adjustment
2. Reduce oseltamivir dose/frequency (e.g., 30 mg PO daily) based on renal impairment (correct answer)
3. Increase oseltamivir to 150 mg PO BID due to reduced drug exposure in CKD
4. Switch to amantadine 100 mg PO BID because it is preferred in CKD

Explanation: This question tests antiviral dosing adjustments in severe renal impairment for influenza treatment. The key patient-specific factor is the 57-year-old female's CKD stage 4 with eGFR 18 mL/min, necessitating oseltamivir reduction. Reducing to 30 mg PO daily is best per guidelines for CrCl <30 mL/min to avoid accumulation. Continuing standard dose risks toxicity, increasing dose is counterproductive, and amantadine is not preferred due to resistance. Distractors ignore renal clearance. A clinical pearl is to adjust oseltamivir based on CrCl for short courses in CKD. This approach ensures effective and safe antiviral therapy.

Question 17

1. Continue vancomycin 1.25 g IV q12h without changes because renal dosing is not required
2. Recommend extending the dosing interval (e.g., 1.25 g IV q24h) with therapeutic drug monitoring (correct answer)
3. Increase vancomycin to 1.5 g IV q8h to overcome reduced renal clearance
4. Switch to nitrofurantoin 100 mg PO BID due to reduced kidney function

Explanation: This question tests vancomycin dosing adjustments in renal impairment to optimize efficacy and minimize nephrotoxicity. The key patient-specific factor is the 66-year-old male's CKD stage 3 with eGFR 32 mL/min, requiring interval extension. Recommending extension to 1.25 g IV q24h with monitoring is best per guidelines for CrCl 30-59 mL/min to maintain therapeutic levels. Continuing q12h risks accumulation, increasing to q8h is excessive, and switching to nitrofurantoin is inappropriate for MRSA. Distractors ignore renal clearance. A clinical pearl is to use trough levels for vancomycin in CKD to guide dosing. This framework ensures safe antibiotic use in renal disease.

Question 18

1. Continue warfarin 4 mg PO daily and continue ibuprofen because INR is only slightly elevated
2. Assess bleeding risk, recommend stopping NSAID, and adjust/hold warfarin dose with closer INR follow-up (correct answer)
3. Administer vitamin K 10 mg IV now because INR is above goal
4. Increase warfarin to 5 mg PO daily because ibuprofen decreases anticoagulation

Explanation: This question tests the management of warfarin-NSAID interactions and elevated INR. The key patient-specific factor is the 75-year-old male's recent ibuprofen use, which potentiates warfarin via platelet inhibition and displacement, causing INR 3.9. Assessing bleeding risk, stopping NSAID, and adjusting warfarin with follow-up is the best step to mitigate risks. Continuing both ignores interaction, high-dose vitamin K is for major bleeding, and increasing warfarin is counterproductive. Distractors miss synergy. A clinical pearl is to avoid NSAIDs in warfarin patients; use acetaminophen instead. This approach reduces bleeding complications.

Question 19

1. Counsel on consistent vitamin K intake and consider increasing weekly warfarin dose with closer INR follow-up (correct answer)
2. Hold warfarin for 2 doses because INR is below goal
3. Administer vitamin K 5 mg PO now to stabilize INR
4. Add aspirin 325 mg PO daily because INR is subtherapeutic

Explanation: This question tests the impact of dietary vitamin K changes on warfarin therapy and INR management. The key patient-specific factor is the 61-year-old female's increased leafy green intake on a keto diet, leading to subtherapeutic INR of 1.7 due to vitamin K antagonism of warfarin. Counseling on consistent vitamin K intake and considering warfarin dose increase with follow-up is the best step to stabilize INR. Holding warfarin or adding aspirin is inappropriate, and vitamin K administration would lower INR further. Distractors overlook dietary influence. A clinical pearl is to maintain consistent vitamin K intake and adjust warfarin based on trends. This approach improves anticoagulation stability.

Question 20

1. Continue current medications and encourage increased free-water intake
2. Hold hydrochlorothiazide and notify the prescriber due to symptomatic hyponatremia (correct answer)
3. Add desmopressin to correct sodium more quickly
4. Start potassium chloride 40 mEq PO daily to correct hyponatremia

Explanation: This question tests the identification and management of drug-induced hyponatremia in susceptible patients. The key patient-specific factor is the 72-year-old female's symptomatic hyponatremia (Na 122 mEq/L) with SIADH history and recent hydrochlorothiazide use. Holding hydrochlorothiazide and notifying the prescriber is the best action as thiazides can exacerbate hyponatremia in SIADH. Continuing the regimen with water intake is insufficient for symptomatic cases, adding desmopressin worsens hyponatremia, and potassium supplementation does not correct sodium. Distractors ignore thiazide's role. A clinical pearl is to suspect thiazides in elderly hyponatremia and monitor electrolytes closely. This framework aids in prompt electrolyte disorder resolution.